A recent study by scientists at the Massachusetts Institute of Technology has culminated in the creation of a detailed atlas of the striatum, a brain region pivotal for various cognitive and motor functions, including decision-making, movement control, and reward processing. This significant advancement, utilizing single-cell RNA sequencing, has unveiled 31 distinct neuronal subgroups, offering profound insights into conditions such as Huntington's disease, addiction, and schizophrenia. These findings are poised to revolutionize the development of new treatments for these complex neurological disorders.
Breakthrough in Striatal Mapping Reveals Disease Mechanisms and Therapeutic Avenues
In a groundbreaking investigation led by Myriam Heiman, Manolis Kellis, and Dana Gabuzda, researchers meticulously mapped the striatum's neuronal landscape. Published on September 1, 2026, in the journal Cell, this collaborative effort between MIT, the Broad Institute, and the Dana-Farber Cancer Institute leveraged advanced single-cell RNA sequencing, multiplexed fluorescent in situ hybridization, and spatial transcriptomics. By analyzing postmortem human striatal samples, the team successfully classified neurons based on their gene expression profiles. Among the 31 identified subgroups, nine were medium spiny neurons, the striatum's most abundant inhibitory neuron type responsive to dopamine.
Key findings include the identification of two "outlier" medium spiny neuron populations (D1 and D2) implicated in addiction, depression, and schizophrenia. The D1 outliers exhibited high expression of genes linked to addiction and opioid response, while D2 outliers showed strong responses to antidepressants. Both populations reacted significantly to clozapine, an antipsychotic drug. This discovery suggests that a deeper understanding of these specific cells could lead to more targeted and safer antipsychotic treatments, circumventing severe side effects associated with current medications. Furthermore, the atlas illuminated why the dorsal striatum is particularly susceptible to Huntington's disease. Researchers found that dorsal medium spiny neurons express elevated levels of MSH2 and MSH3 genes, which are involved in increasing detrimental CAG repeats in the huntingtin gene. Conversely, a rare population of island-forming medium spiny neurons in the ventral striatum demonstrated resistance to these repeats, offering potential clues for inducing resilience in other vulnerable neurons. The study also highlighted species-specific differences in drug response genes between human and mouse striatum, particularly regarding the mu opioid receptor (OPRM1). This suggests that refining mouse models to better mimic human gene expression could significantly enhance the accuracy of addiction research.
This comprehensive brain atlas serves as an invaluable resource for the scientific community, providing a foundational roadmap for future research into neurological disorders. The detailed characterization of neuronal populations and their roles in various conditions opens new doors for developing innovative, targeted therapies. This work underscores the critical importance of interdisciplinary collaboration and advanced genomic techniques in unraveling the complexities of the human brain and addressing some of the most challenging health issues of our time.